Contract for Biomarker Servic

RNS Number : 3139A

Proteome Sciences PLC

31 January 2011

 



Proteome Sciences plc

Proteome Sciences Closes Contract for Biomarker Services with Eisai

31^st January 2011 - Proteome Sciences plc (AIM:PRM) is pleased to announce that it has entered into a PS Biomarker Services™ contract with Eisai Ltd ("Eisai"). PS Biomarker Services™ will provide measurement of candidate biomarkers for Alzheimer's disease using its AD-TMT-SRM assay set on human sample material.

Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences said:

"We are delighted to add Eisai to the growing list of PS Biomarker Services™ clients. As a global pharmaceutical company, Eisai has the opportunity to select from many contract service organisations and they have recognised the advantages of using our mass spectrometric assay capabilities, acknowledging our strong track record of delivery in biomarker discovery and validation, as well as rapid MS assay development."

Ends

For further information please contact:

Proteome Sciences plc
www.proteomics.com	Tel: [phone]
Christopher Pearce, Chief Executive Officer	[e-mail]
James Malthouse, Finance Director	[e-mail]
Dr. Ian Pike, Chief Operating Officer Dr. Rainer Voegeli, Commercial Director	[e-mail] [e-mail]
Nominated Adviser
Singer Capital Markets Limited
Shaun Dobson/Claes Spång
Tel: [phone]
Public Relations
IKON Associates	Redleaf Communications Limited
Adrian Shaw	Anna Dunkin/Lucy Salaman
Tel:       [phone]	Tel:       [phone]
Mobile: [phone]	Email:   [e-mail]
Email:   [e-mail]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and uses high sensitivity proprietary technologies for protein biomarker discovery, validation and assay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications. These biomarkers are available for outlicensing. The first blood test for lung cancer using Proteome Sciences' biomarkers was launched in the USA in 2009 and received Medicare reimbursement in 2010. Its PS Biomarker Services™ provides ISO 9001: 2008 accredited facilities in Frankfurt, Germany, using proprietary isobaric and isotopic Tandem Mass Tags^® (TMT^®) to discover protein biomarkers, and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in validation studies. Assays for validated biomarkers can be transferred for immunoassay development. Proteome Sciences, based in Cobham, UK, has facilities in London and Frankfurt and delivers outsourced proteomics services and proprietary biomarkers to pharmaceutical, biotechnology and diagnostics companies. Visit http://www.proteomics.com.

 

END

 

 

CNTEAPFPAFFFEFF